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Abstract 
 
Background:  Sialic acid and cholesterol are present in human milk and accumulate 
rapidly in the brain during development.  Infant formulas contain little sialic acid or 
cholesterol.  Sialic acid and cholesterol supplementation increase cortical ganglioside 
and glycoprotein sialic acid and cholesterol in animal models, respectively.  Dose-
response studies and those varying both sialic acid and cholesterol intake are lacking. 
Objective:  The purpose of this study was to determine the effects of bovine casein 
glycomacropeptide (CGMP) and dietary cholesterol on cortical ganglioside- and 
glycoprotein-bound sialic acid accumulation in young rats. 
Design/Methods:  Dams were fed a nutritionally complete rat diet with 0 or 0.5% 
cholesterol by weight throughout pregnancy and lactation.  Litters were culled to 8 
pups on postnatal day (P) 1.  Coagulated milk was removed from the stomach of P1 
pups and the cholesterol concentration determined.  After weaning, two pups from 
each litter were allocated to one of four diets varying in CGMP (provided 
approximately 0, 20, 40 and 80 mg sialic acid/kg d-1) and the same cholesterol 
concentration as their dams.  In the first experiment, the dams’ litters were weaned on 
P17 to the sialic acid-supplemented diets and sacrificed on P32.  In the second 
experiment, litters were weaned on P21 to the diet of their dams.  Pups consumed the 
dams’ diets until P24 or P33 and their assigned sialic acid-supplemented diets 
thereafter.  The pups were sacrificed between P38 and P47, 14 days after the initiation 
of the sialic acid-supplemented diets.  On the day of sacrifice, pups were decapitated 
and their brains immediately frozen on dry ice.  Gangliosides and glycoproteins were 
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extracted from the cortex and the sialic acid concentration determined. 
Results:  Maternal cholesterol intake increased total milk cholesterol (p = 0.0009).  In 
pups sacrificed on P32, CGMP increased cortical ganglioside sialic acid in a dose-
response manner (p for trend = 0.007).  In the same experiment, dietary cholesterol 
independently increased ganglioside sialic acid (p = 0.02).  In pups sacrificed between 
P38 and P47, cholesterol intake increased glycoprotein sialic acid (p = 0.030). 
Conclusions:  Increased sialic acid and cholesterol consumption during the first 4 
weeks of postnatal brain growth influenced brain composition in rats.
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Chapter 1 Introduction 
 
The sialic acid, N-acetylneuraminic acid (Neu5Ac), and cholesterol are 
important components of the brain that accumulate rapidly during development.  All 
human milk provides Neu5Ac and cholesterol, but infant formulas contain little to 
none of these biomolecules (1, 2).  Among exclusively breast-fed infants, Neu5Ac 
intake accounts for 0.1% (wt/vol) of the diet in the first two weeks of life (1).  
Although the concentration of Neu5Ac in human milk exponentially decreases within 
the first 2 months of lactation, it continues to serve as a significant component of the 
diet throughout the first 7 months (1).  In contrast, infant formulas contain less than 
25% of the sialic acid found in mature human milk and include a higher proportion of 
total sialic acid bound to glycoproteins compared to free oligosaccharides (2).   
Similarly, human milk contains 10-11 mg of cholesterol per deciliter, while cows' 
milk-based and soy-based formulas contain 3-5 mg/dL and 0 mg/dL, respectively (3). 
Neu5Ac and cholesterol serve several important functions in the brain.  
Neu5Ac is a structural and functional component of gangliosides and glycoproteins 
and is involved in a variety of membrane-related events, including cellular 
recognition, adhesion, and signal transduction (4).  A few studies suggest an 
endogenous source of Neu5Ac is important for proper neural development during 
infancy, and studies employing the use of animal models demonstrate a positive 
correlation between the concentration of Neu5Ac in the brain and learning 
performance (5, 6).  In 1980, Morgan and Winick found that intraperitoneal 
administration of Neu5Ac during the first 30 days of life significantly increased 
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Neu5Ac incorporation in brain gangliosides and glycoproteins of well-fed and 
undernourished rat pups and permanently reduced the expected behavioral 
abnormalities secondary to malnutrition (6, 7).  Similar effects have been observed 
with oral administration of sialic acids (5) and early environmental stimulation (6, 8).    
Cholesterol plays an important role in neuroarchitecture and the transmission 
of neural impulses.  It is a key component of neuronal cell membranes, nerve growth 
cones, and myelin (9).  Cholesterol is not uniformly distributed in neuronal cell 
membranes, but is concentrated in microdomains, called lipid rafts.  These 
heterogeneous areas in the membrane are enriched in gangliosides and thought to 
function as a platform for signaling pathways (10, 11).  Observational studies in 
humans have linked total serum cholesterol with measures of cognitive function, such 
as verbal fluency, concentration, and abstract reasoning (12).   
Rapid growth in infancy can increase the requirement for exogenous sources 
of nutrients.  It is important to determine if dietary Neu5Ac and cholesterol consumed 
from milk can influence the accumulation of these compounds in the brain during this 
critical period of brain growth and development.  Previous studies demonstrate that 
dietary Neu5Ac can increase cortical ganglioside and glycoprotein-bound Neu5Ac (1, 
5), but few have investigated the dose-response effects of Neu5Ac supplementation.  
Studies varying both sialic acid and cholesterol intake are also lacking.   
The purpose of this project was to determine if glycomacropeptide, a 
concentrated source of sialic acid found in bovine milk, and dietary cholesterol 
influence cortical ganglioside- and glycoprotein-bound Neu5Ac accumulation in 
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young rats.  Three specific research questions were addressed: 
1. Does postnatal administration of glycomacropeptide increase the 
concentration of cortical ganglioside- and glycoprotein-bound sialic acid in 
developing rats? 
2. Does exposure to dietary cholesterol during gestation, lactation and 
postweaning influence the accumulation of cortical sialic acid? 
3. Do quantitative differences in cortical ganglioside- and glycoprotein-bound 
sialic acid exist among rats administered glycomacropeptide at various 
maturational stages? 
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Chapter 2 Review of Literature 
Sialic Acids 
 Sialic acids comprise a large family of nine-carbon α-keto acids derived from 
3-deoxy-non-2-ulosonic acid (13).  The structure of sialic acids assumes a chair 
conformation and includes a deoxy moiety adjacent to the anomeric carbon, a 
glycerol branch at C6, and a carboxylate group at C1 (13).  Under physiological 
conditions, the carboxylate group confers a negative charge on the molecule and 
characterizes it as a strong organic acid (pKa 2.2) (14, 15). 
 Naturally occurring sialic acids can be divided into three major types, based 
on the functional group located at C5.  The substituent can be an acetamido, a 
glycolyl, or a hydroxyl group, forming N-acetylneuraminic acid (Neu5Ac), N-
glycolylneuraminic acid (Neu5Gc), and 2-keto-3-deoxy-D-glycero-D-galacto-nonoic 
acid (KDN), respectively (15, 16) (Figure 1).  The hydroxyl groups located on 
carbons 4, 7, 8, and 9 can be further modified by phosphorylation, methylation, 
acetylation, lactylation or sulfonation, producing over 50 structurally distinct 
compounds with unique properties (13, 15, 16).  Unsaturated sialic acids and internal 
anhydro linkages have also been observed (15). 
 
 
Figure 1.  Three basic forms of naturally occurring sialic acids.  
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Sialic acids are commonly located on the distal end of glycan chains 
conjugated with lipid or protein scaffolds.  The penultimate glycan residue typically 
consists of glucose, galactose, N-acetyl-galactosamine, or N-acetyl-glucosamine, 
linked to a sialic acid through α-(2-6) or α-(2-3)-linkages (13).  Although sialic acids 
are primarily present as monosialyl residues, disialic residues may be formed at the 
distal end of glycan chains through α-(2-4), α-(2-8) or α-(2-9)-linkages (13).  Linear 
homopolymeric structures of sialic acid attached to glycoproteins have also been 
observed in several species (13, 15, 16), with chain lengths varying from 8 to 200 
residues.  These negatively charged, voluminous polymers vary in both monomer 
type and linkage (16).  Thus far, α-(2-8), α-(2-9), alternating α-(2-8)/α-(2-9), and α-
(2-5)Oglycolyl-linkages have been described (16). 
 Due to their outmost positioning and hydrophilic character, sialic acids exert a 
physiochemical force on their environment and mediate several important cellular 
recognition and adhesion processes (14, 17).  Sialic acid residues bind and transport 
positively charged molecules, attract and repel cells, serve as antigenic determinants, 
and function as an antiproteolytic shield for glycoproteins (14, 15).  They are 
necessary components of receptors for endogenous substances, such as hormones and 
cytokines, as well as pathogenic agents, including toxins, viruses, bacteria, and 
protozoa (14, 15).  Sialic acids function as ligands for receptors, such as lectins, 
selectins, and members of the sialoadhesion family, mediating a variety of processes 
involved in the immune response and cell migration (13, 14, 15).  They also 
participate in the carbohydrate-protein interactions responsible for promoting cell 
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growth, cell differentiation, fertilization, and oncogenesis (13).  
    
N-acetylneuraminic Acid 
 N-acetylneuraminic acid (Neu5Ac) is the most abundant sialic acid in nature 
(4, 14, 17) and is found in high concentration in neural cell membranes and human 
milk (1, 2).  Its synthesis is compartmentalized within the cell and begins in the 
cytosol (14) with the formation of N-acetylmannosamine (ManNAc) from UDP-N-
acetylglucosamine (UDP-GlcNAc) (17) (Figure 2).  This reaction, catalyzed by  
 
 
 
Figure 2.  The biosynthesis of CMP-Neu5Ac in mammals. 
 
UDP-GlcNAc 2-epimerase (GNE), both hydrolyzes the glycosidic phosphate bond 
and inverts the stereochemistry at C2 (17).  In mammals, ManNAc is phosphorylated 
by ManNAc kinase to produce ManNAc 6-phosphate (ManNAc-6P), and Neu5Ac-9-
P synthase catalyzes the condensation of ManNAc-6P with phosphoenolpyruvate to 
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give Neu5Ac 9-phosphate (Neu5Ac-9P) (17).  It is worth noting that the human form 
of Neu5Ac-9-P synthase can also accept mannose 6-phosphate as an alternative 
substrate in this pathway, generating KDN 6-phosphate (17).  This is not true for all 
eukaryotic forms of the enzyme, including that of the rat (17).  
After dephosphorylation of Neu5Ac-9P by Neu5Ac-9-P phoshatase, Neu5Ac 
is transported to the nucleus, where it is converted to its active form (14, 17).  This is 
accomplished through the addition of a cytidine monophosphate (CMP) residue from 
cytidine triphosphate (CTP) by CMP-Neu5Ac synthetase (14, 17).  CMP-Neu5Ac is 
then translocated into the Golgi apparatus or the endoplasmic reticulum, where it 
serves as the substrate for all sialytransferases.  These enzymes transfer Neu5Ac to 
the oligosaccharide chain of nascent glycoproteins and glycolipids (14, 17). 
Interestingly, CMP-Neu5Ac is the only sialic-acid containing molecule where the 
anomeric configuration is β (13, 14). 
 Two other metabolic pathways for the synthesis of Neu5Ac are known, 
including the condensation of enolpyruvate phosphate and ManNAc, catalyzed by 
Neu5Ac synthase, and an aldol reaction between pyruvate and ManNAc, catalyzed by 
acylneuraminate pyruvate-lyase (18).  The enzyme that facilitates the first reaction 
pathway has only been described in pathogenic strains of bacteria that display sialic 
acids on their cell surface to mimic mammalian cells and conceal antigenic sites, 
including Neisseria meningitidis, Escherichia coli K1, and Campylobacter jejuni (17, 
18).  The latter enzyme, acylneuraminate pyruvate-lyase, is present in both bacteria 
and mammals.  However, bacteria that express acylneuraminate pyruvate-lyase do not 
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synthesize Neu5Ac, and this enzyme is absent from mammalian tissues that 
continuously produce sialic acids (18).  It is thought that acylneuraminate pyruvate-
lyase is involved in catabolic, rather than anabolic reactions (18).  This idea is 
supported by the position of the equilibrium of the reaction, which is unfavorable for 
Neu5Ac synthesis (18). 
 The primary enzymes involved in Neu5Ac catabolism are carbohydrate-
specific sialidases (14).  Sialidases hydrolyze the glycosidic linkage between Neu5Ac 
residues and the penultimate sugar of the oligosaccharide chain of glycoproteins and 
glycolipids (14).  In higher animals, glycoconjugates are generally taken up by 
receptor-mediated endocytosis.  After fusion of the endosome with a lysosome, the 
terminal Neu5Ac residues are removed by lysosomal sialidases (14).  Free Neu5Ac 
molecules are transported through the lysosomal membrane into the cytosol (14).  
Here, they can be further degraded by acylneuraminate lyases or recycled by 
activation and transferred onto another nascent glycoprotein or glycolipid molecule 
(14).  Alternatively, Neu5Ac residues can be removed from glycoproteins and 
glycolipids on the cell surface by membrane-bound sialidases (14).   
     
Ganglioside-bound N-acetylneuraminic Acid 
As previously mentioned, sialytransferases located in the Golgi apparatus and 
endoplasmic reticulum transfer Neu5Ac residues to the oligosaccharide chain of 
nascent glycoproteins and glycolipids.  Neu5Ac serves as a structural and functional 
component of both glycoproteins and glyolipids. 
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Glycolipids contain one or more monosaccharide residues covalently bound to 
a hydrophobic moiety, such as an acylglycerol, a sphingoid, a ceramide, or a prenyl 
phosphate, by a glycosidic linkage (19, 20).  Glycolipids are membrane-anchored and 
the carbohydrate structures are exposed at the cell surface (21).  To date, more than 
300 glycolipids have been isolated and characterized according to their lipid and 
carbohydrate moieties (19, 20).  Those containing one or more sialic acid residues 
belong to a family of acidic glycosphingolipids and are designated 
sialoglycosphingolipids or gangliosides (19). 
Gangliosides are commonly named according to a convention established by 
Lars Svennerholm (1963), in which a ganglioside is specified by the letter G followed 
by M, D, T, or Q, indicating the presence of one, two, three, or four sialic acid 
residues, respectively (19).  A number, which initially referred to the migration order 
of the ganglioside, is then assigned to each individual compound (19).  These 
designations are not systematic and do not correlate with the molecular structure of 
the ganglioside (19).  For example, the structure of GD3 is 
Neu5Acα8Neu5Acα3Galβ4GlcCer.  Nevertheless, Svennerholm’s abbreviations are 
used because they are short and well understood (19).  
 De novo synthesis of gangliosides begins with the formation of ceramide at 
the cytosolic leaflet of the endoplasmic reticulum membrane (22, 23, 24).  Serine 
palmitoyl transferase catalyzes the condensation of L-serine and a fatty acyl 
coenzyme A, typically palmitoyl coenzyme A, to form 3-ketosphinganine (22, 23).  
This molecule is reduced to D-erythro-sphinganine by 3-ketosphinganine reductase 
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and acylated to dihydroceramide by an N-acyltransferase (22, 23).  Ceramide is 
produced through the desaturation of dihydroceramide in a reaction catalyzed by 
dihydroceramide desaturase (22, 23).  
Ceramide is a lipid biomodulator of various cellular functions and serves as 
the membrane anchor of all glycosphingolipids and sphingomyelin (22, 23, 24).  To 
continue ganglioside biosynthesis, ceramide is transferred to the cytosolic leaflet of 
the Golgi apparatus with the aid of the ceramide transfer protein (CERT) (23).  Here, 
a glucose residue is β-glycosidically linked to the 1-position of ceramide, forming 
glucosylceramide (GlcCer) (21, 22, 23).  This reaction is catalyzed by 
glucosylceramide synthase and utilizes uridine diphosphoglucose as the glycosyl 
donor (21, 22, 23).  Alternatively, ceramide may be galactosylated by 
galactosyltransferase to form galactosylceramide.  This precursor is needed to 
synthesize sulfatides and GM4, a major ganglioside of the myelin membrane (22, 23).  
At this point, GlcCer can reach the plasma membrane by direct transport or be further 
modified by glycosylation on the luminal leaflet of the Golgi membranes (22).  The 
latter is necessary for ganglioside synthesis.  Galactosyltransferase-I catalyzes the 
addition of a galactose moiety from uridine diphosphogalactose to glucosylceramide, 
producing lactosylceramide (LacCer) (21, 22, 23).   
With the exception of GM4, all gangliosides are synthesized through the 
stepwise addition of monosaccharide residues onto LacCer from sugar nucleotide 
donors imported from the cytoplasm (22, 23, 25).  Addition of the first Neu5Ac 
residue converts LacCer to GM3 in a reaction catalyzed by either GM3-synthase or 
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sialyltransferase I (ST-I) (22, 23).  GM3 is the precursor of most complex brain 
gangliosides, and subsequent addition of Neu5Ac residues generates gangliosides 
GD3 and GT3 (23).  These reactions are catalyzed by structurally and genetically 
distinct enzymes, termed GD3-synthase or ST-II and GT3-synthase or ST-III, 
respectively (23).  Collectively, GM3, GD3, and GT3 are known as the hematosides 
or sialyl-lactosylceramides.  Together with LacCer, they serve as the entry substrates 
for the synthesis of complex gangliosides in the a-, b-, c-, and 0-series pathways (22, 
23).  To date, about 200 gangliosides differing in carbohydrate constituents have been 
identified, but those from the 0- and c-series are only found in trace amounts in adult 
human tissues (22, 23).  
 Gangliosides are typical components of vertebrate cells and are 
asymmetrically located in the outer molecular leaflet of the plasma membrane (26, 
27, 28).  Although they are present in virtually every cell type, they are especially 
concentrated in the central and peripheral nervous systems (CNS and PNS) (23, 26, 
27).  Gangliosides are most abundant in areas predominating in neuronal cell bodies, 
such as the cerebral gray matter, cerebellar gray matter, and caudate nucleus (29).  
The lowest concentrations occur in areas consisting largely of myelinated fiber tracts 
and glial cells, as in the cerebral white matter, pons, medulla, and corpus callosum 
(29).  This concentration differential is observed due to the specific localization of 
gangliosides in dendritic and axonal neuronal membranes and their synaptic 
connections (26, 28, 29).  Although some gangliosides are present in the myelin 
membrane, they are virtually absent from glial cells, producing a 10-fold difference in 
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ganglioside-bound Neu5Ac between gray and white matter (29).    
Studies using monoclonal antibodies and thin layer chromatography have 
revealed that single ganglioside species are specifically distributed in nervous tissues 
and signaling pathways (30, 31).  For example, the gray matter of the mammalian 
brain primarily consists of GM1, GD1a, GD1b, GT1b, and GQ1b, whereas the white 
matter predominantly contains GM1 and GD1a (31).  Similarly, GM1 accounts for 
15% of the total ganglioside in motor nerve myelin, while only trace amounts are 
observed in sensory nerve myelin (31).  In 1999, Vorwerk et al. discovered that the 
ceramide composition of GD1a, GD1b, and GM1 also varies between human motor 
and sensory nerves and, later, published data supporting a link between the 
ganglioside distribution patterns in the human spinal cord and function (31).   
Gangliosides are known to play crucial modulatory roles in several 
membrane-related phenomena, including cellular recognition, adhesion, interaction, 
and signal transduction (23, 26, 30).  Although some of the mechanisms by which 
gangliosides interact with their surrounding environment are not well understood, the 
concept of a multifunctional role for gangliosides seems suitable to explain their 
different functional implications (23, 26).   
The Neu5Ac residues, and the other oligosaccharide components of 
gangliosides that protrude from the cell surface, possess the potential to interact with 
external ligands (26).  This allows gangliosides to function as receptors for bioactive 
molecules and mediators of cellular recognition and adhesion (32).  At least 11 
Neu5Ac-binding proteins, or lectins, have been identified in humans (33, 34).  
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Together, they are designated as members of the Siglec family (33, 34).  While some 
are highly specific for a single type of Neu5Ac linkage, others appear less selective 
(33).  A common example is the binding of myelin-associated glycoprotein (MAG) 
with gangliosides GD1a and GT1b.  MAG is a quantitatively minor protein found on 
the innermost periaxonal myelin membrane and functions as a myelin-stabilizing 
factor and inhibitor of nerve regeneration (33, 35).  In order to elicit its physiological 
effects, MAG must bind to the Neu5Ac residues of GD1a and GT1b on the neuronal 
membrane (33, 35).  Gangliosides exhibiting other Neu5Ac linkages fail to support 
MAG-mediated adhesion (33, 35).  Studies have demonstrated that mice lacking the 
ability to synthesize GD1a and GT1b display progressive neurodegenerative 
abnormalities, including axon degeneration and demyelination in the CNS and PNS 
(33, 35).  Thus, this ganglioside-specific adhesion process is required for long-term 
axon stability (33, 35).  Recent evidence suggests that GT1b can also facilitate the 
interaction between MAG and the Nogo-66 receptor 1, a neuronal protein required for 
acute growth cone collapsing (36, 37), providing another example of ganglioside-
mediated cellular communication.  Other important Neu5Ac-binding lectins include 
the B-lymphocyte surface receptor CD22, CD33, and sialoadhesin (33, 34).   
Gangliosides also exert a physiochemical force on extracellular substances 
(26).  A noteworthy example is the interaction between Neu5Ac residues on 
astrocytic gangliosides and extracellular matrix-associated laminin.  Laminin is a 
large extracellular glycoprotein that has been implicated in the morphogenesis of the 
nervous system (38).  In adult basement membranes, laminin is spatially separated 
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from the bulk extracellular matrix and is organized in a continuous mesh-like network 
(38).  During embryonic development, however, laminin appears as cell-surface-
associated deposits or is arranged in large polymeric aggregates scattered within the 
extracellular space (38).  These morphologies tend to restrict or permit neurite 
outgrowth, respectively (38).  Observations from in vitro and cell-free studies suggest 
that gangliosides on the surface of astrocytes guide the formation of these laminin 
polymers (38).  Removal of Neu5Ac residues on embryonic monolayers by 
neuraminidase treatment leads to the immediate release of matrix-associated laminin 
and converts the laminin matrix to a more restrictive form after reassembly (38).  A 
related phenomenon is observed in artificial lipid films.  Films containing GT1b or a 
mixture of gangliosides favor a more permissive morphology, while those consisting 
of phophatidylcholine or GM1 tend to inhibit the growth of neurites (38).  This 
suggests that the number of Neu5Ac residues present on the surface of astrocytes 
plays a prominent role in directing the assembly of laminin matrices (38). 
 In the plasma membrane, gangliosides are believed to segregate into 
microdomains enriched in glycosylphosphatidylinositol (GPI)-anchored proteins, 
sphingomyelin, and cholesterol (23, 26, 39, 40).  These domains are variously 
referred to as lipid rafts, detergent-resistant membranes, and detergent-insoluble 
glycosphingolipid-enriched domains (40).  Although the exact function of lipid rafts 
is not fully understood, they appear to change the biophysical properties of the lipid 
bilayer and facilitate ganglioside interaction with membrane proteins, such as 
receptors, enzymes, ion channels, and ion pumps (23, 26, 39).  For example, 
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ganglioside GD1a has been shown to increase the excitability of voltage-dependent 
batrachotoxin-modified sodium channels derived from rat brain (41).  This equips 
neurons with an additional tool for regulating their excitability and is thought to 
ensure proper synaptic transmission (41).  Gangliosides also modulate calcium 
exchange between the extracellular space and synaptoplasm, which may contribute to 
memory formation through stabilization of synaptic contacts (41, 42). 
By interacting with functional proteins, gangliosides may also facilitate 
metabolic second messenger production, signal transduction, and cellular responses 
based on protein phosphorylation and dephosphorylation processes (23, 26, 32, 43).  
Gangliosides have the capacity to produce metabolic second messengers of sphingoid 
nature (26).  Ceramide and sphingosine are potent regulators of protein kinase C and 
other protein kinases and enzymes involved in signal transduction (26).  A possible 
mechanism for the formation of these second messengers is the intra-lysosomal 
breakdown of membrane-bound gangliosides after ligand-mediated endocytosis (26). 
 
Glycoprotein-bound N-acetylneuraminic Acid 
Sialytransferases in the Golgi apparatus and endoplasmic reticulum also 
transfer Neu5Ac residues to the oligosaccharide chain of nascent glycoproteins.  
Glycoproteins are macromolecules which consist of heteropolymerized carbohydrate 
sub-units covalently attached to amino acids of a polypeptide backbone (44, 45).  
Glycoproteins are ubiquitous in all forms of life, and protein glycosylation is a typical 
post-translational modification of most enzymes, receptors, antibodies, hormones, 
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cytokines, and structural proteins (44).  The carbohydrate, or glycan, can range in size 
from one to hundreds of monosaccharides and may form linear or branched polymers 
(44).  The number of glycans present can also vary greatly between proteins (44). 
A striking feature of almost all glycoproteins is the polymorphism associated 
with their glycan moieties (44).  Individual molecules of a given glycoprotein can 
carry different oligosaccharides at the same glycosylation site of the protein backbone 
(44).  This phenomenon is known as microheterogeneity, and the resulting variants 
are referred to as glycoforms (44).  Microheterogeneity was originally thought to be 
the result of a lack of fidelity in glycoprotein synthesis (44).  Recent evidence 
suggests that under constant physiological conditions, the set of observed glycoforms 
is reproducible and highly regulated (44).  The population of glycoforms has also 
been shown to change during cell growth, cell differentiation, and malignant 
transformation, suggesting that defined sets of glycoforms are required for normal 
functioning (44).  
Three major types of linkages covalently attach glycans to the amino acids of 
a polypeptide backbone (44).  These include N-glycosidic linkages, O-glycosidic 
linkages, and GPI anchors (44).  N-glycosidic linkages result from the transfer of a 
common core pentasaccharide from the donor molecule dolichol pyrophosphate to the 
amide nitrogen atom in the side chain of asparagine (21, 44, 46).  After trimming of 
the core pentasaccharide, nucleotide-activated monosaccharides are sequentially 
added to the terminal mannose residues by glycosyltransferases located in the 
endoplasmic reticulum and Golgi apparatus (21, 45, 46).  Glycosyltransferases 
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display distinctive substrate-, cell-type-, and developmental-stage-specificity, 
producing glycans with great diversity (21, 45).  
The core pentasaccharide of N-glycosidic linkages, which consists of three 
mannose and two N-acetylglucosamine residues, can only be transferred to an Asn-X-
Ser or Asn-X-Thr sequence, where X can be any residue, except proline (21, 44, 46).  
This allows potential glycosylation sites to be detected within the amino acid 
sequence (46).  However, not all potential sites are glycosylated, and those selected 
depend on both the structure of the protein and the cell type in which it is expressed 
(44, 46).  For example, mechanistic studies demonstrate that the enzyme responsible 
for forming N-glycosidic linkages, oligosaccharyl transferase, may only glycosylate 
peptides which are able to adopt the Asx-turn conformation (44).    
O-glycosidic linkages typically occur between the side chain hydroxyl group 
of serine or threonine and the reducing end of monosaccharide residues (21, 44, 46).  
Although less common, the side chain hydroxyl groups of hydroxyproline, 
hydroxylysine, and tyrosine can also support O-glycosidic linkages (44).  Unlike N-
glycosylation, biosynthesis of O-glycan chains takes place exclusively in the Golgi 
apparatus and begins with the addition of single nucleotide-activated 
monosaccharides to the protein backbone, producing a variety of carbohydrate-
protein linkages (21, 44, 46).   
GPI anchors are structurally unrelated to N-glycosidic and O-glycosidic 
linkages and involve the attachment of a glycolipid to a nascent protein during post-
translational modification.  Specifically, GPI anchors link the C-terminal amino acid 
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of a protein to an oligosaccharide attached to phosphatidylinositol via ethanolamine 
phosphate (44). This reaction is catalyzed by GPI transamidase in the endoplasmic 
reticulum and occurs rapidly upon completion of protein translation and translocation 
(47).  GPI anchors are important because they provide a means for anchoring proteins 
with a wide variety of structures and biological functions to the extracellular surface 
of the plasma membrane (44, 47). 
  The most common monosaccharides incorporated into glycoproteins include 
galactose, glucose, mannose, N-acetylegalactosamine, N-acetylglucosamine, L-
fucose, and Neu5Ac (44, 45).  Neu5Ac residues are invariably located at the terminal 
end of glycan chains, with galactose or N-acetlygalactosamine serving as the 
penultimate monosaccharide (45).  This outermost positioning is observed because 
Neu5Ac residues are rarely attached to the polypeptide backbone (39), and no further 
chain elongation is possible after the addition of Neu5Ac, except for the formation of 
Neu5Ac polymers (44).  In the brain, N-glycans and O-glycans predominantly carry 
α-(2,3)-linked Neu5Ac, with little or no α-(2,6)-linked Neu5Ac, while Neu5Ac 
polymers typically consist of α-(2,8)-linkages (21).  Because Neu5Ac is a common 
component of many glycoproteins and microheterogeneity is abundant, only a 
summary of the general location and functions of Neu5Ac-containing glycoproteins, 
or sialoglycoproteins, will be presented.   
Many glycoproteins are located in the cytoplasm, subcellular organelles, and 
extracellular fluid, while others, including sialoglycoproteins, are components of the 
plasma membrane (44, 45, 46).  Hydrolysis experiments have revealed that 
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sialoglycoproteins and gangliosides share a similar distribution pattern in the CNS 
(29).  Like gangliosides, sialoglycoproteins are most abundant in areas predominating 
in neuronal cell bodies, including the cerebral gray matter, cerebellar gray matter, and 
caudate nucleus, while the lowest concentrations occur in areas consisting primarily 
of myelinated fibre tracts and glial cells, as in the cerebral white matter, pons, 
medulla, and corpus callosum (29).  Relative to sialoglycoproteins, gangliosides are 
slightly more concentrated in the gray matter (29).  This observation may be due to 
the activity of membrane-bound sialidase (14, 29).  While the regional distribution of 
sialidase parallels the distribution of total Neu5Ac, its activity is much greater in the 
gray matter (29).  Roukema and Heijlman (1970) suggest gangliosides contain less 
hydrolyzable Neu5Ac or are less accessible to sialidase than sialoglycoproteins, due 
to the aggregation of gangliosides on the plasma membrane (29).  This would result 
in the preferential hydrolysis of the Neu5Ac residues attached to sialoglycoproteins, 
producing a lower ratio of sialoglycoproteins to gangliosides in the gray matter.   
While the regional distribution of sialoglycoproteins is similar to that of 
gangliosides, they do not appear to share the same subcellular localization (29, 48).  
Gangliosides and sialoglycoproteins primarily occur in the crude mitochondrial and 
microsomal fractions sedimented from rat whole brain (29, 48).  Exposure of the 
crude mitochondrial fraction to osmotic shock before density-gradient centrifugation 
reveals that the largest percentage of gangliosides and sialoglycoproteins is found in 
synaptosomes (29, 48).  If the synaptosome-enriched fraction is subjected to a more 
extensive fractionation, sialoglycoproteins sediment into more dense subfractions, 
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while gangliosides appear more evenly distributed (29, 48).  This differential 
sedimentation suggests that sialoglycoproteins and gangliosides are found in different 
subcellular locations (29, 48). 
There is no single unifying function for the carbohydrates present in 
glycoproteins (44, 49).  While some participate in physiological and pathological 
recognition events, others modify the chemical, physical, and biological properties of 
the proteins to which they are attached (44, 49).  The same glycan may also display 
distinct functions at separate locations on a given protein, or in different cell types or 
developmental stages (49).  In a manner similar to the single oligosaccharide unit of 
gangliosides, the glycan moieties of membrane-bound sialoglycoproteins, such as 
prions, integrins, CD34, and the neural cell adhesion molecule, penetrate through the 
lipid bilayer and extend into the extracellular fluid (39, 45).  Here, Neu5Ac residues 
regulate several cellular adhesion processes, acting as a lubricant that modulates the 
interaction between sterically masked ligands (45, 50).  For example, the α-(2,6)-
linked, Neu5Ac residues of integrins serve as antiadhesion molecules and mediate the 
migration and differentiation of neural progenitors derived from embryonic striatum 
(39).  Investigators suggest these biological functions are conferred by the anionic 
character of Neu5Ac, which may hinder adhesion by electrostatically repelling other 
ionized residues on nearby cells (45, 50).  Alternatively, the negative charge may 
function as a barrier to cellular interaction, blocking access to adhesion sites located 
beneath the Neu5Ac residues on the cell surface (44, 45).  This observation may help 
account for the ability of Neu5Ac to increase the stability of glycoproteins (50).  The 
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residues may cover functionally important areas of the protein, protecting the peptide 
backbone from recognition by proteases and antibodies (44, 49).   
In addition to the chemical structure of Neu5Ac, the context of its presentation 
is also critical to its function (39).  A single Neu5Ac residue has little biological 
activity, but achieves its specificity through multivalency and the clustering of the 
residues attached to a specific sialoglycoprotein (39).  An example of cluster-
dependent function is provided by CD34, a stem cell antigen expressed by 
proliferating resident microglia in response to acute neural injury (39, 52).  The N 
terminus of CD34 is heavily glycosylated with Neu5Ac and protrudes a considerable 
distance from the cell membrane (53).  This region is thought to adopt the 
conformation of an extended rod, forming a cellular halo of Neu5Ac-dependent 
negative charge (53).  Together, the Neu5Ac residues possess an anti-adhesive quality 
and function as a barrier to cell-cell interaction (53).  Ganglioside-bound Neu5Ac 
also requires clustering to elicit a biological effect and is achieved through the 
aggregation of gangliosides in lipid rafts (39).   
A sialoglycoprotein that plays a particularly important role in brain 
development and neuronal plasticity is the neural cell adhesion molecule (NCAM).  
NCAM is a member of a large family of membrane-bound glycoproteins that share 
structural motifs related to immunoglobulin and fibronectin type II domains (54).  It 
is unique among recognition molecules in that its adhesive and signal transduction 
functions are modulated by polysialic acid (PSA), a linear homopolymer containing 
up to 200 α-(2,8)-linked Neu5Ac residues (21, 55, 56).  Unlike most carbohydrates 
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displayed on the cell surface, PSA is exclusively attached to NCAM, an observation 
supported by the nearly complete absence of PSA in NCAM-deficient mice (56).  
PSA is added to NCAM post-translationally by one of two Golgi-associated 
polysialytransferases, namely ST8SiaIV (PST) and ST8SiaII (STX) (21, 56).  These 
enzymes attach PSA to two asparagines in the Ig5 module of the extracellular portion 
of NCAM (21, 56).   While PST is primarily expressed in the adult, STX is more 
highly expressed during development (21).  After developmental events cease, 
NCAM typically shifts from a PSA-rich to a PSA-poor form (21, 54, 56, 57).  
Interestingly, STX continues to be expressed and PSA is retained in areas of the adult 
brain that display the capacity for morphological and physiological plasticity, 
including the neuroblasts of the rostral migratory stream and the innermost granule 
cell layer of the hippocampal dentate gyrus (21, 39, 54, 57).  Immature neurons in the 
dentate gyrus mature and integrate into the neuronal network in an activity-dependent 
manner (21).  Once these neurogenic stem cells differentiate, their expression of PSA 
is reduced (21).  Remarkably, the expression of PSA on NCAM in neuroblasts is 
enhanced after training in spatial memory tasks, when new connections might need to 
be formed or when a synapse might undergo morphological changes (21).  Based on 
these activities, it is not surprising that NCAM is connected with learning and 
memory consolidation (39, 56).  The loss of PSA eliminates the anti-adhesive 
character of this surface protein and, subsequently, appears to halt the migration of 
neuroblasts to the outer part of the granular layer and promote the stabilization of 
synaptic contacts (21, 54).  Similarly, removal of PSA from NCAM by endosialidase 
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N alters the outgrowth or sprouting of axons, neuronal and glial migration, axonal 
pathfinding, axon branching, and fasciculation (21, 39, 54).  
  
Developmental Regulation of Gangliosides and Sialoglycoproteins 
The expression of ganglioside- and glycoprotein-bound Neu5Ac in the 
nervous system is developmentally regulated and closely related to the differentiation 
state of the cell (21, 23).  During development, gangliosides undergo characteristic 
changes in content and composition (58, 59).  The total concentration of ganglioside-
bound Neu5Ac in the forebrain increases in two distinct phases (59).  In humans, the 
first phase occurs between the 13th and 30th week of gestation, and the second occurs 
from birth to 9 months of age (59).  These phases correspond to the time of rapid 
multiplication of neurons and the extensive establishment of micro-neuronal 
interconnections, respectively (59).  The concentration of ganglioside-bound Neu5Ac 
in the cerebellum also increases from birth to 9 months of age (59).  In contrast, no 
appreciable change is observed in the brainstem after 30 weeks of gestation (59).  
Nine months after birth, the total concentration of ganglioside-bound Neu5Ac in the 
human brain reaches the adult level and begins to plateau (59).  
The composition of gangliosides in the brain also changes during development 
and is regulated by the activities of glycosyltransferases through gene transcription 
and posttranslational modification (23, 58, 59).  After birth, GM1, GD1a, GD1b, and 
GT1b account for 90% of the total gangliosides found in the human brain (59).  At 
the 15th week of gestation, GT1b accounts for approximately 38% of the total 
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gangliosides in the forebrain on a molar basis, while GD1a accounts for about 26% 
(59).  The proportion of GD1a increases rapidly until the 20th week of gestation and 
more slowly up to the 35th week (59).  This is followed by a rapid increase to term, 
when GD1a accounts for roughly 70% of the total gangliosides (59, 60).  After birth, 
this proportion decreases to about 50% and remains stable through 26 months of age 
(59).  In contrast, the molar percentage of GT1b decreases to 10% at birth and 
remains constant through the first two years of life (59, 60).  The fraction of GD1b 
falls from 20% at 13 weeks of gestation to 5% at term, and then increases again to the 
adult level of 15% by 9 months of age (59).  After an initial decrease, GM1 increases 
to a level of 25-30% one year after birth and remains stable thereafter (59). 
A similar pattern is observed in the cerebellum, and the contributions of GD1a 
and GT1b appear to change reciprocally throughout development (59).  However, 
GT1b serves as the predominant fraction in the cerebellum, rather than GD1a (59).  
Just as no appreciable change in concentration is observed in the brainstem after 30 
weeks of gestation, the ganglioside pattern also remains constant (59).  These 
maturational changes appear to be functionally involved in the control of axonal and 
dendritic outgrowth, synaptogenesis, and the establishment of cell contact (58, 60). 
The overall pattern of gangliosides in the brain approaches that of the adult 2 
years after birth (59).  As adults mature, the ganglioside composition shifts to a more 
polar pattern, due to the relative increase in GQ1b, GT1b and GD1b and decrease in 
GD1a and GM1 (58).  With the exception of GQ1b, the absolute concentration of all 
gangliosides decreases with age (58).  In a study on 9 neurologically normal males 
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ranging from 25 to 85 years of age, Segler-Stahl et al. found a decrease in 
ganglioside-bound Neu5Ac from 1,070 to 380 μg/g of fresh brain tissue (58).  This 
may help account for the progressive degeneration of myelin sheaths, deterioration of 
dendrites, and loss of neurons and synapses observed in the aging brain (58).  
The concentration of sialoglycoproteins appears to increase at the same time 
as gangliosides and correlates with the outgrowth of cell processes (61, 62).  In rats, 
the most rapid increase in sialoglycoproteins occurs between 4 and 18 days after birth 
(61, 62).  Evidence suggests the rate of sialoglycoprotein biosynthesis during 
postnatal development is not limited by the activities of CMP-N-acetylneuraminic 
acid synthetase or glycoprotein sialytransferase, but may depend on the production of 
endogenous acceptors, or the precursors of sialoglycoproteins (62).   
As mentioned in the discussion of NCAM, PSA is highly expressed in the 
embryo and neonate and exhibits a decreased and more restricted expression in adults 
(55, 57).  This observation is partly due to the expression of the polysialytransferases, 
PST and STX.  Both enzymes are prevalently expressed during development, starting 
from E8-E9 in rodents, and are downregulated in the adult (56).  While STX declines 
dramatically after birth, PST declines more gradually and is continuously expressed at 
lower levels through adulthood (56).  Similarly, NCAM begins to be expressed at the 
time of neural tube closure and remains detectable at lower levels in the adult (55). 
The expression of PSA-NCAM also fluctuates with circadian rhythms and the 
ovarian cycle (56).  The concentration of PSA in the mammalian suprachiasmatic 
nucleus, a structure responsible for maintaining circadian rhythms synchronized to 
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the light/dark cycle, fluctuates rhythmically and is characterized by high levels during 
the day and low levels at night (56).  Studies carried out on the Syrian hamster have 
revealed that a 90% reduction in PSA occurs during the mid-to-late dark phase, and 
maximum concentration is reached 1 hour after the lights are turned on (56).  During 
the proestrous phase of the ovarian cycle, PSA-NCAM becomes more heavily 
associated with axon terminals of the gonadotropin-releasing hormone (GnRH) 
neurons in the glial processes and median arcuate nucleus (56).  These structures are a 
part of the GnRH neurosecretory system and undergo dynamic structural and 
functional changes during the ovarian cycle (56).   
Interestingly, the expression of PSA-NCAM also fluctuates during lactation.  
Compared to virgin rats, PSA-NCAM dramatically decreases in the neurohypophysis 
and supraoptic nuceli during lactation (56).  This decrease is not associated with 
modifications in the amount of NCAM present or changes in the splicing pattern of 
NCAM mRNAs.  It is solely dependent on the expression of PSA, and the 
concentration of PSA-NCAM returns to its initial value after weaning (56).  
  
N-acetylneuraminic Acid in Infancy  
 Rapid growth and development of the brain in infancy may place exceptional 
demand on the endogenous synthesis of Neu5Ac (2, 4, 39).  While the livers of all 
mammals have the capacity to synthesize Neu5Ac from simple sugar precursors, 
those of newborn infants are relatively immature, and the activity of the rate-limiting 
enzyme, GNE, is low during the neonatal period (2, 5, 39).  This may limit de novo 
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synthesis, causing Neu5Ac to become a conditionally essential nutrient during this 
critical period of neurological development (2, 4, 39).  
It is well known that human milk serves as an endogenous source of Neu5Ac 
after birth (1, 2, 5, 63, 64).  Evidence also suggests a significant amount of Neu5Ac is 
provided through the placenta (63).  In a study of 219 pregnant women, Alvi et al. 
found a graded and significant increase in the mean serum Neu5Ac with progressing 
pregnancy (65).  The concentration of serum Neu5Ac ranged from 1.635 ± 0.302 
mmol/L at the onset of pregnancy to 2.064 ± 0.494 mmol/L after 37 weeks (65).  An 
inverse pattern is observed in the Neu5Ac content of human milk during lactation.  In 
1985, Carlson found a mean concentration of oligosaccharide-bound Neu5Ac ranging 
from 1138 ± 86 mg/L during the first two weeks of lactation to 135 ± 16 mg/L after 
10 weeks (1).  If one assumes an average milk consumption of 100 kcal/kg body 
weight/day with an average energy content of 670 kcal/L, this corresponds to a mean 
daily intake of 170 mg/kg body weight and 20 mg/kg body weight, respectively (1).  
The concentration of glycoprotein-bound Neu5Ac was also observed to decrease 
throughout lactation, ranging from 267 ± 24 mg/L in the first two weeks to 73 ± 8 
mg/L after 10 weeks (1).  Wang et al. found a similar distribution of Neu5Ac in 
human milk, and noted that milk from mothers of preterm infants contains 13-23% 
more Neu5Ac at 3 of the 4 lactation stages than milk from mothers delivering full-
term infants (2).  Based on these observations, it appears that the highest 
concentration of Neu5Ac is provided before and shortly after birth, during the 
developmental spurt of brain-mass accretion (5).  This may help compensate for the 
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limited rate of Neu5Ac synthesis in infancy. 
It is important to note that the concentration of sialic acid in human milk 
varies dramatically among individuals when controlled for lactation duration (1, 66).  
In 2007, Bao et al. observed high variation in sialyloligosaccharides that could not be 
accounted for by the intrinsic variation in the method employed, suggesting 
significant biological differences in expression of acidic milk oligosaccharides (66).  
The composition of oligosaccharides present in human milk is related to the 
expression and activity of two fucosyltransferases and four phenotypic groups, 
consistent with the Lewis blood group system, have been identified (67, 68).   
Relative to human milk, infant formulas contain very little sialic acid.  The 
sialic acid content of most infant formulas is less than 25% of that found in mature 
human milk, and typically ranges from 0.05 ± 0.003 mmol/L in soy milk formulas to 
0.63 ± 0.12 mmol/L in preterm formulas (2).  The sialic acid contained in infant 
formulas is also more likely to be bound to glycoproteins, rather than free 
oligosaccharides (2), and the concentration of lipid-bound Neu5Ac has been shown to 
be two times higher in human milk than cow’s milk and formula milk (69).  Thus, 
exclusive consumption of infant formulas may limit Neu5Ac accumulation in the 
brain during infancy (2, 63, 70).   
In 2003, Wang et al. determined the Neu5Ac concentration of 25 samples of 
postmortem cerebral tissue derived from infants who died of sudden infant death 
syndrome (70).  After adjustment for age at death with sex as a covariate, the average 
concentration of ganglioside- and glycoprotein-bound Neu5Ac was 32% and 22% 
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higher, respectively, in breastfed than formula-fed infants (70).  Experimental studies 
employing the use of animals have also demonstrated that an exogenous source of 
Neu5Ac may play a role in determining the final concentration of Neu5Ac in the 
brain, and several have noted behavioral and neuronal changes.  In 1980, Morgan and 
Winick demonstrated that Neu5Ac administered through intraperitoneal injection can 
improve learning performance and increase the concentration of cerebral and 
cerebellar ganglioside- and glycoprotein-bound Neu5Ac in well-fed and under-
nourished rat pups (7, 8).  They found similar benefits in rats exposed to 
environmental stimulation during the first 21 days of postnatal life (8).  Early 
stimulation caused undernourished rats to exhibit a pattern of behavior that more 
closely resembled that of well-fed rats and resulted in changes in brain composition 
that persisted into adulthood (8).  This suggests that there is more than one 
mechanistic route to achieve an optimal Neu5Ac concentration in the brain (8, 39).   
In 1986, Carlson and House proved that oral administration of Neu5Ac can 
also increase the concentration of cerebral and cerebellar ganglioside- and 
glycoprotein-bound Neu5Ac in young rats (71), and, later, Park et al. achieved similar 
results when feeding rats a ganglioside-enriched diet (72).  In 2007, Wang et al. 
conducted a study in which piglets were randomly allocated to receive a sow milk 
replacer containing 140, 300, 635, or 830 mg of sialic acid/L from bovine casein 
glycomacropeptide (CGMP) (5).  In a dose-response manner, sialic acid 
supplementation was associated with faster learning, increased protein-bound sialic 
acid in the frontal cortex, and amplified expression of two key enzymes involved in 
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Neu5Ac metabolism, namely PST and GNE (5).  Previous studies have revealed that 
the intracellular concentration of sialic acid regulates the amount of PSA on NCAM 
(51).  The findings of Wang et al. suggest the reverse is also true (5).  Increases in the 
polysialylation of NCAM appear to up-regulate sialic acid synthesis (5).  This would 
explain why sialic acid supplementation correlated with an unexpected increase in 
GNE expression (5). 
Several studies have demonstrated that exogenously administered 
gangliosides promote neurite outgrowth in vitro and potentiate neurotrophic factor 
effects (31).  Others indicate efficacy of GM1 treatment for individuals with CNS 
ischemia and spinal cord lesions (31).  In 1984, Sabel et al. showed that 30 mg/kg 
injections of GM1 in adult rats could reduce behavioral deficits after brain injury by 
enhancing structural reorganization of remaining afferents or preventing secondary 
neuronal degeneration (73).  Similar benefits were observed by She et al. after lead-
induced impairment of synaptic plasticity in rats (74).  Intraperitoneal administration 
of gangliosides was shown to significantly increase the amplitude of the population 
spike and slope of the excitatory post-synaptic potential compared to unsupplemented 
rats (74).  This suggests gangliosides may reverse lead-induced impairments of 
synaptic plasticity and attenuate the cognitive deficits induced by lead (74).        
Genetic and chromosomal mutations affecting Neu5Ac metabolism or the 
ability to synthesize complex gangliosides result in several neurological 
abnormalities.  Mice lacking complex gangliosides exhibit decreased central 
myelination, axonal degeneration, loosened myelin sheaths, and demyelination in 
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peripheral nerves (75, 76).  They also display a reduction in nerve conduction 
velocity and expression of MAG in the CNS (75, 76).  In 2004, Simpson et al. found 
that human autosomal recessive infantile-onset symptomatic epilepsy syndrome is 
associated with a loss-of-function mutation in GM3 synthase, the key enzyme for the 
synthesis of all complex gangliosides (77).  With the onset of seizure activity, 
affected children show stagnation in the acquisition of developmental milestones and 
experience neurological decline (78).  In 2007, Gulesserian et al. found a five-fold 
reduction in the concentration of Neu5Ac synthase in the cortex of fetuses with Down 
syndrome compared to controls (79).  This significantly alters Neu5Ac metabolism 
and may help account for the cognitive impairment observed in this disorder (79).  
Alcohol consumption also appears to affect Neu5Ac metabolism.  In 1989, 
Prasad administered a moderate dose of alcohol to rats throughout gestation and 
found an increase in the total ganglioside-bound sialic acid, a decrease in ganglioside 
catabolizing enzymes, and altered proportions of individual ganglioside fractions in 
the brains of the rat pups at birth (80).  Tomás et al. later found that ethanol impairs 
the uptake of sialic acid in cultured rat astrocytes, but significantly increases the 
uptake of its precursor, ManNAc (81).  This suggests that the carbohydrate 
transporters located in the plasma membrane are altered by alcohol and may serve as 
a target for the deleterious effect of ethanol on brain development (81). 
 
Digestion and Absorption of Sialic Acids 
Hydrolysis of sialic-acid-containing carbohydrates in the lumen of the small 
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intestine is achieved by sialidases in the intestinal mucosa (4, 82).  Due to their 
terminal position, the bond between sialic acid residues and the penultimate sugar of 
the oligosaccharide chain may be cleaved even if the remainder of the chain resists 
digestion (4).  Interestingly, sialidase activity in the middle and distal thirds of the 
small intestine increases rapidly after birth in several species and is positively 
correlated with the sialic acid concentration of milk collected from the mothers at 
corresponding times post partum (82).  Autohydrolysis of sialic acid residues in the 
intestine may also occur because sialic acids are relatively strong organic acids (4). 
In 1981, Nöhle and Schauer demonstrated that the intestinal cell walls of rats 
are highly permeable to free sialic acid (83).  N-Acetyl-D-[2-14C,9-3H]neuraminic 
acid, enzymically prepared from sodium [2-14C]-pyruvate and N-acetyl-D-[6-
3H]mannosamine by N-acetylneuraminate lyase in 75% yield, was orally 
administered to 20 day old fasted mice (83).  Approximately 90% of the administered 
neuraminic acid was absorbed from the intestine in the course of 4 hours, at a rate 
depending on the retention time of neuraminic acid in the intestine and the mental 
conditions of the animals (83).  This observation may not apply to human digestion 
and absorption of sialic acid.  In 1998, Brand-Miller et al. demonstrated that most 
human milk oligosaccharides resist digestion in the small intestine and undergo 
fermentation in the colon (84), and in vitro studies have confirmed that sialic acid is 
not released from the incubation of human milk oligosaccharides with pancreatic and 
mucosal enzyme mixtures (85).  It is possible that sialidases of bacterial origin cleave 
sialic acid residues from milk oligosaccharides in the colon, but it is not known if 
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sialic acid can be absorbed across the colonic mucosa (4). 
 
Casein Glycomacropeptide (CGMP) 
CGMP is a C-terminal glycopeptide released from -casein by the action of 
chymosin during cheese making and contains various amounts of covalently linked 
oligosaccharides, including galactose, N-acetylgalactosamine, and Neu5Ac (86, 87).  
The oligosaccharide chains of CGMP are attached to the peptide backbone at four 
threonine residues (numbers 131, 133, 135, and 142) and serine-141 (88).  These sites 
are glycosylated at random and exhibit a large degree of heterogeneity (88).  Due to 
the relative abundance of Neu5Ac, CGMP has been a proposed source of Neu5Ac 
supplementation for infant formulas.  The carbohydrate profile of CGMP varies 
widely, depending on the isolation method, but CGMP typically provides 
approximately 60 mg of sialic acid/g (5, 86).  Although less abundant, bovine milk 
oligosaccharides also contain N-glycolylneuraminic acid (89).  For this reason, 
caution should be exercised in the use of CGMP for human consumption.    
    
N-glycolylneuraminic acid 
 The majority of vertebrates, including the Great Apes, are able to oxidize the 
α-carbon of the N-acetyl group within CMP-Neu5Ac to produce CMP-Neu5Gc (14, 
15, 90).  However, due to a frameshift mutation resulting in the lack of a 92 bp region 
of cDNA, humans are unable to produce the enzyme responsible for catalyzing this 
reaction, CMP-Neu5Ac hydroxylase (15, 90, 91).  Traces of Neu5Gc have been 
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detected in healthy and malignant human tissues, but no enzymatic activity has been 
reported (91).  It was previously thought that the expression of Neu5Gc was 
dependent on malignant transformation of the tissue (14).  New evidence suggests the 
small amount of Neu5Gc present in human tissues originates from exogenous sources 
(90).  In a study by Tangvoranuntakul et al., human volunteers consumed 150 mg of 
porcine submaxillary mucin Sias (95% Neu5Gc) (90).  Although a portion was 
absorbed and eliminated in the urine, a small quantity of free Neu5Gc was 
metabolically incorporated into newly synthesized glycoproteins (90).  This is 
concerning because humans produce variable amounts of IgA, IgM, and IgG 
antibodies against Neu5Gc, and Neu5Gc is a common compound found in milk 
products, lamb, pork, and beef (90).  The incorporation of this nonhuman dietary 
component may potentially create an autoreactive situation (90), and should be 
addressed if manufacturers attempt to supplement infant formulas with Neu5Ac.  
 Interestingly, the results obtained by Tangvoranuntakul et al. contrast those 
obtained in a mouse model, where 98% of radioactively labeled Neu5Gc was 
absorbed from the intestine and appeared unaltered in the urine 6 hours after oral 
administration (92).  This suggests animal models for Neu5Gc metabolism and 
excretion may have limited generalizability to humans. 
  
Cholesterol in Infancy 
  Cholesterol is another component of human milk that is not currently included 
in infant formulas.  Human milk typically contains 10-11 mg of cholesterol per 
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deciliter, while cows' milk-based and soy-based formulas contain 3-5 mg/dL and 0 
mg/dL, respectively (3, 93).  Although evidence suggests the cholesterol-synthesizing 
machinery is well developed in neonates and premature infants (94), it is well 
documented that infants fed human milk down-regulate cholesterogenesis and have 
higher plasma cholesterol concentrations than formula-fed infants (3, 95, 96).  This 
suggests an endogenous source of cholesterol may still be important during this 
period of rapid development. 
 Cholesterol plays an important role in neuroarchitecture and the transmission 
of neural impulses.  It is a key component of neuronal cell membranes, nerve growth 
cones, and myelin (9).  Cholesterol promotes synaptogenesis and up-regulates genes 
that influence the development of dendritic spines and neurotransmitter receptors 
(97).  It also serves as a precursor of various metabolically active compounds such as 
hormones, oxysterols, and bile salts (94).  Observational studies in humans have 
linked total serum cholesterol with measures of cognitive function, such as verbal 
fluency, concentration, and abstract reasoning, and inborn errors in cholesterogenesis 
lead to severe congenital defects and mental retardation (12, 94).     
In neuronal cell membranes, cholesterol is not uniformly distributed, but is 
concentrated in lipid rafts.  These heterogeneous areas are enriched in gangliosides 
and hypothesized to function as a platform for signaling pathways (10, 11, 40).  The 
inclusion of cholesterol in lipid rafts increases the fluid character of the plasma 
membrane and facilitates ganglioside interaction with membrane proteins (26, 39).  
This suggests the concentration of cholesterol in the membrane may influence the 
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functional properties of gangliosides, and several studies demonstrate cholesterol 
depletion leads to perturbation of raft-mediated signaling (40).  Interestingly, 
treatment of astrocytes with the cholesterol-solubilizing detergent methyl-β-
cyclodextrin results in the release of extracellular laminin (38).  A similar result is 
observed upon removal of Neu5Ac residues with neuraminidase treatment, suggesting 
Neu5Ac and cholesterol work in tandem to permit or restrict neurite outgrowth (38).        
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Chapter 3 Materials and Methods 
 
Overview 
The purpose of this study was to determine the impact of glycomacropeptide 
and dietary cholesterol on cortical ganglioside- and glycoprotein-bound sialic acid 
accumulation in young rats.  Rat pups were allocated to receive one of four dietary 
glycomacropeptide treatments (0, 14.0, 28.1, and 56.2 g/kg) for two weeks and 
exposed to 0 or 0.5% dietary cholesterol by weight throughout gestation, lactation, 
and postweaning.  These doses were selected to represent the range of intake typically 
observed in human milk- and formula-fed infants, and provided approximately 0, 20, 
40 and 80 mg sialic acid/kg d-1.  The concentration of ganglioside- and glycoprotein-
bound sialic acid was determined through established methods (98, 99, 100), and the 
cholesterol content of the dams’ milk was determined according to Rosenthal et al.   
 
Setting 
 This study was conducted at the University of Kansas Medical Center, Kansas 
City, Kansas.  The animals were raised between November 2006 and June 2007.   The 
analysis of ganglioside- and glyprotein-bound sialic acid and milk cholesterol was 
performed between August 2007 and November 2008. 
 
Ethics 
The study protocol followed the National Research Council’s guide for the 
care and use of laboratory animals and was approved by the Institutional Animal Care 
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and Use Committee at the University of Kansas Medical Center (2006-1585). 
 
Materials 
Female Long-Evans rats (Blue Spruce) were purchased from Harlan Inc. 
(Indianapolis, IN) (n/group = 12) and bred with proven male breeders (Blue Spruce, 
Harlan Inc., Indianapolis, IN).  Throughout pregnancy and lactation, the rats 
consumed a nutritionally complete rat diet (AIN-93G, Harlan Teklad, Madison, WI) 
with or without cholesterol (0.5 or 0% by weight).  All litters were culled to 8 pups on 
postnatal day (P) 1.  After weaning, two pups from each litter were housed together 
and allocated to each of four diets varying in CGMP (0, 14.0, 28.1, and 56.2 g/kg to 
provide approximately 0, 20, 40 and 80 mg sialic acid/kg d-1, respectively) and the 
same cholesterol level as their dams.  During this portion of the study, the base diet 
(AIN-93G) was modified slightly with casein and corn starch to ensure similar total 
protein and carbohydrate concentrations at all CGMP levels (Table 1). 
 
Sialic Acid Supplementation after Early Weaning 
In the first experiment, the dams’ litters were weaned early on P17.  The sialic 
acid-supplemented diets were fed from weaning to P32, when the pups were 
sacrificed.  The diets were formulated with the Tatua (Morrinsville, New Zealand, 67 
mg sialic acid/g) source of CGMP.  Experiment one followed the intended 
experimental design and was conducted from February to June 2007. 
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Table 1.  Composition of the cholesterol-supplemented rat pup diets1 
 0 mg 
Neu5Ac/kg/d 
20 mg 
Neu5Ac/kg/d 
40 mg 
Neu5Ac/kg/d 
80 mg 
Neu5Ac/kg/d 
AIN-93 G2       4650 g        4650 g        4650 g 4650 g 
Soybean Oil         350 g  350 g  350 g   350 g 
Casein3        48.0 g 36.0 g 24.0 g − 
Corn Starch4          8.2 g 6.15 g   4.1 g − 
Glycomacropeptide5 −       14.05 g 28.1 g  56.2 g 
Cholesterol6 25 g            25 g            25 g     25 g 
 
1The composition of the non-cholesterol diets was identical to the diets shown 
above, excluding the 25 g of cholesterol at each level. 
2AIN-93G was purchased from Harlan Tekland (Madison, WI) in powdered form. 
3,4Glycomacropeptide was 85% protein and 15% carbohydrate by weight.  Casein 
and corn starch were added to compensate for glycomacropeptide at the three 
lower glycomacropeptide concentrations fed. 
5Two sources of glycomacropeptide were used for the experiment: Tatua Co-
Operative Dairy Company, Morrinsville, New Zealand, 67 mg sialic acid/g and 
Arla Food Ingredients, Denmark, 55 mg sialic acid/g. The composition shown in 
Table 1 was for the product from Tatua Co-operative Dairy Co.  
6Cholesterol was dissolved in the soybean oil prior to mixing with dry ingredients. 
 
Post-weaning Sialic Acid Supplementation 
Due to a delay in arrival of the Tatua product (approximately 3 months), we 
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attempted to salvage the designed study by feeding CGMP later, after the period of 
maximal ganglioside- and glycoprotein-bound sialic acid accumulation in brain.  The 
diets in the second experiment were formulated with the Arla product (Denmark, 55 
mg sialic acid/g), which arrived after all rat pups had exceeded 17 days of age.  
Litters were weaned on P21 to the diet of their dams (Table 2).  Rat pups consumed 
 
Table 2.  Composition of dams’s non-cholesterol and cholesterol supplemented diets 
 Non-Cholesterol Diet 0.5% Cholesterol Diet 
AIN-93 G1                4650 g               4650 g 
Soybean Oil                  350 g                 350 g 
Cholesterol2 −                   25 g 
 
1AIN-93G was purchased from Harlan Tekland (Madison, WI) in powdered form. 
2Cholesterol was dissolved in the soybean oil prior to mixing with dry ingredients. 
 
the dams’ diets until P24 to P33.  Pups received their assigned sialic acid-
supplemented diets for 14 days and, therefore, were sacrificed between P38 and P47.  
The decision to analyze the brains in the second experiment was made with the intent 
of determining how timing of CGMP intake might influence composition. 
 
Quantification of Ganglioside- and Glycoprotein-bound Sialic Acid 
On the day of sacrifice, the pups were decapitated and the brains immediately 
frozen on dry ice.  Gangliosides were extracted from the cortex according to the 
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procedure outlined by Svennerholm and Fredman (98), and the resulting pellet was 
analyzed for glycoprotein-bound sialic acid (Appendix A).  The concentration of 
ganglioside- and glycoprotein-bound sialic acid was determined using the HCl-
resorcinol method (99), as modified by Suzuki (100) (Appendix B).  The samples 
were read using a BioSpec-mini spectrophotometer at 620 nm to negate the 
contamination of other sugars (98), and the concentrations were calculated by 
equations derived from standard Neu5Ac solutions (Metreya LLC, Pleasant Gap, 
PA).  A standard curve was analyzed with each set of samples.  All sets were 
balanced to include equal numbers of brains from each of the 8 dietary treatments. 
 
Analysis of Milk Cholesterol 
 Coagulated milk was removed from the stomach of P1 pups and stored at        
-80°C in an ultra-low temperature freezer (Legaci®, Asheville, NC) until the day of 
analysis.  After saponification in 10% ethanolic potassium hydroxide (101), the 
concentration of total milk cholesterol was determined by the method of Rosenthal et 
al. (102) (Appendix C).  Because the treatment of dams was identical through P1 in 
both experiments and not all litters required culling, the stomach contents from one 
pup in each available litter from both experiments were analyzed.   
 
Statistical Analysis of Data  
Differences in ganglioside-bound sialic acid were determined using a mixed 
model ANOVA with subject as a random effect (SAS® version 9.2, SAS Institute 
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Inc., Cary, NC).  Even with a daily standard curve, there were effects of day of 
analysis on sialic acid concentration.  Therefore, each day of analysis was treated as a 
block to decrease the random error introduced by day to day environmental variation 
(e.g., room temperature and humidity), with cholesterol and concentration of sialic 
acid intake as main effects.  Glycoprotein-bound sialic acid data were analyzed using 
an ANOVA model that treated cholesterol and day as fixed effects and concentration 
of sialic acid intake as a fixed covariate interaction (SAS® version 9.2, SAS Institute 
Inc., Cary, NC). Differences in total milk cholesterol were determined using 
Student’s t distribution (Microsoft® Excel 2007).  
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Chapter 4 Results 
Sialic Acid Supplementation after Early Weaning 
Seven rat pups in the first experiment died before the date of sacrifice, 3 of 
which received the diet including cholesterol supplementation (0.5% cholesterol by 
weight).  Glycomacropeptide intake independently and significantly increased (linear 
trend for dose) cortical ganglioside-bound sialic acid (p = 0.007) (Figure 3).  
 
Figure 3.  Mean (±SE) concentrations of cortical ganglioside-bound sialic acid in 
rats fed diets containing 0% and 0.5% cholesterol by weight.  Glycomacropeptide 
independently and significantly increased (linear trend for dose) cortical 
ganglioside-bound sialic acid (p = 0.007) (n = 10 at 0 mg sialic acid/kd·d-1; n = 11 
at all other levels of supplementation).  Dietary cholesterol significantly increased 
ganglioside-bound sialic acid (p = 0.02) (n = 10 at 40 mg sialic acid/kd·d-1; n = 11 
at all other levels of supplementation).  Specific values are listed in Appendix D. 
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As Figure 1 shows, exposure to dietary cholesterol during gestation, lactation, and 
postweaning also significantly increased cortical ganglioside-bound sialic acid (p = 
0.02).  The concentration of cortical glycoprotein-bound sialic acid was not 
influenced by glycomacropeptide or cholesterol intake.  The average concentration of 
cortical glycoprotein-bound sialic acid was 0.258 and 0.257 mg/g brain (wet weight) 
in the non-cholesterol and cholesterol supplemented groups, respectively. 
 In a separate analysis, the influence of dietary cholesterol on cortical 
cholesterol and protein accumulation was examined.  Exposure to dietary cholesterol 
significantly increased cortical cholesterol and protein in P32 rat pups (Table 3).  
 
Table 3.  Mean (±SE) cortical cholesterol and protein per gram of brain in P32 pups 
 Cortical Cholesterol  Cortical Protein 
Non-Cholesterol Diet 11.71 ± 0.20 mg/g       96.59 ± 1.75 mg/g 
Cholesterol Diet 12.61 ± 0.25 mg/g     101.29 ± 1.30 mg/g 
P-value1 0.006 0.034 
 
1Differences in cortical cholesterol and protein were determined using Student’s t 
distribution (Microsoft® Excel 2007) (n = 43/group in the analysis of cortical 
cholesterol; n = 39/group in the analysis or cortical protein).  
 
Post-weaning Sialic Acid Supplementation 
 In the second experiment, two rat pups receiving the cholesterol-supplemented 
diet died before the day of sacrifice.  Exposure to dietary cholesterol significantly 
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increased the concentration of glycoprotein-bound sialic acid, but did not affect the 
concentration of ganglioside-bound sialic acid (Table 4).  Glycomacropeptide intake 
did not influence ganglioside- or glycoprotein-bound sialic acid (data not shown).  
 
Table 4.   Mean (± SE) cortical ganglioside- and glycoprotein-bound sialic acid per 
gram of brain with post-weaning sialic acid supplementation 
 Ganglioside-bound Sialic Acid 
Glycoprotein-bound 
Sialic Acid 
Non-Cholesterol Diet 1113.39 ± 12.61 μg/g 0.177 ± 0.007 mg/g 
Cholesterol Diet 1103.49 ± 12.47 μg/g 0.200 ± 0.008 mg/g 
P-value1 — 0.030 
  
1Differences in ganglioside- and glycoprotein-bound sialic acid were determined 
using a mixed model ANOVA (SAS® version 9.2, SAS Institute Inc., Cary, NC) 
(n = 44 in the non-cholesterol diet; n = 42 in the cholesterol-supplemented diet).  
  
The effect of dietary cholesterol on cortical cholesterol and protein 
accumulation was also examined in the second experiment.  Exposure to dietary 
cholesterol increased cortical protein, but did not significantly influence the 
concentration of cortical cholesterol (Table 5). 
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Table 5.   Mean (±SE) cortical cholesterol and protein per gram of brain with post-
weaning sialic acid supplementation 
 Cortical Cholesterol  Cortical Protein 
Non-Cholesterol Diet 10.72 ± 0.17 mg/g 124.14 ± 1.38 mg/g 
Cholesterol Diet 11.13 ± 0.17 mg/g 129.33 ± 1.37 mg/g 
P-value1 0.099 0.009 
 
1Differences in cortical cholesterol and protein were determined using Student’s t 
distribution (Microsoft® Excel 2007) (n = 44 in the non-cholesterol diet; n = 42 in 
the cholesterol-supplemented diet). 
 
Analysis of Milk Cholesterol 
Maternal cholesterol intake significantly increased the cholesterol 
concentration of milk collected from the stomachs of culled P1 rat pups (p = 0.0009).  
The average concentration of milk cholesterol on P1 was 55.83 ± 9.45 ( x ± SD; n = 
17) and 70.51 ± 13.23 ( x ± SD; experiment one: n = 16) mg/dL in pups consuming 
milk from non-cholesterol and cholesterol supplemented dams, respectively. 
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Chapter 5 Discussion 
Sialic Acid Supplementation after Early Weaning 
 In the first experiment, glycomacropeptide independently and significantly 
increased cortical ganglioside-bound sialic acid in a dose-response manner, but did 
not influence glycoprotein-bound sialic acid.  The overall concentration of 
ganglioside-bound sialic acid was similar to that observed in study by Carlson and 
House, in which rats received Neu5Ac through intraperitoneal injection or intubation 
(72).  This suggests the sialic acid contained in CGMP is bioavailable, and CGMP 
may be a viable source of sialic acid for supplementation in the future.   
In a related study, Park et al. observed similar increases in ganglioside-bound 
sialic acid when administering a ganglioside-rich diet (0.1% w/w of total fat) to rats 
for two weeks, beginning on P18 (72).  Interestingly, the investigators observed a 
highly significant reduction in the ratio of cholesterol to ganglioside-bound sialic acid 
in the brain of rats consuming the ganglioside-rich diet compared with animals fed a 
control diet (72).  A small reduction in the ratio of cholesterol to ganglioside-bound 
sialic acid was also observed when feeding a diet containing sphingomyelin (1% w/w 
of total fat) (72), a precursor to the membrane anchor of gangliosides.  However, 
when the investigators examined the overall concentration of cholesterol in the brain, 
animals fed the sphingomyelin diet did not exhibit any change in total cholesterol 
content in the brain, while those consuming the ganglioside-rich diet had a 
significantly lower concentration of brain cholesterol (72).  This suggests dietary 
sialic acid, rather than the lipid portion of gangliosides, plays a functional role in 
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reducing brain cholesterol.  Park et al. suggests dietary gangliosides decrease brain 
cholesterol by influencing lipid and protein trafficking in lipid rafts (72).  
In the present study, dietary cholesterol significantly increased ganglioside-
bound sialic acid and cortical cholesterol in P32 rat pups.  The concentration of 
cholesterol in the brain is tightly regulated and not typically influenced by the diet.  In 
attempt to determine whether cholesterol in milk influences growth and the sterol 
composition of brain, Edmond et al. fed milk substitutes containing variable amounts 
of cholesterol to artificially reared rat pups from P5 until P15 or 16 (103).  The 
investigators found that the sterol composition of brain was not influenced by the 
concentration of cholesterol in milk and that cholesterol exogenous to brain, even in a 
hypercholesterolemic condition, did not gain entry to the brain (103).  Based on the 
findings of Edmond et al. and Park et al., it is possible that dietary cholesterol did not 
increase the concentration of cortical cholesterol, but sialic acid supplementation 
reduced cortical cholesterol in rats lacking dietary cholesterol.  The results of the 
present study also indicate that low dietary cholesterol may limit ganglioside-bound 
sialic acid accumulation in the cortex.  Together, these findings suggest cholesterol 
supplementation may be important during this period of development.   
 
Post-weaning Sialic Acid Supplementation 
 In the second experiment, glycomacropeptide intake did not influence 
ganglioside- or glycoprotein-bound sialic acid.  The overall concentration of 
ganglioside-bound sialic acid in both dietary groups was greater than that observed at 
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the highest level of sialic acid and cholesterol supplementation in the first experiment.  
This suggests early consumption of sialic acid and cholesterol can accelerate the 
accumulation of ganglioside-bound sialic acid to a maximal concentration, but that 
animals will eventually reach this concentration even if they do not consume sialic 
acid or cholesterol.  Although the concentration of cortical ganglioside-bound sialic 
acid plateaued by 38 to 47 days of age, it is possible that earlier accumulation of sialic 
acid provides a functional advantage to the developing rat pup. 
 It is interesting to note that cholesterol supplementation did not significantly 
increase cortical cholesterol in the second experiment, and the overall concentration 
of cortical cholesterol was lower in both dietary treatments.  If dietary sialic acid truly 
reduces the concentration of cholesterol in the cortex, supplementation only appears 
to influence cortical cholesterol during the period of ganglioside-bound sialic acid 
accumulation.  As the concentration of ganglioside-bound sialic acid in both dietary 
groups plateaued, significant differences in cortical cholesterol were not observed.  
Although not significant, a slightly lower concentration of ganglioside-bound sialic 
acid was also related to a higher concentration of cortical cholesterol.  The overall 
reduction in cortical cholesterol observed in the second experiment also suggests a 
higher level of cholesterol supplementation may be needed during the period of 
ganglioside-bound sialic acid accumulation to maintain cortical cholesterol. 
 The overall concentration of glycoprotein-bound sialic acid in both dietary 
groups was lower than that observed in the first experiment.  This is likely due to 
decreased expression of polysialic acid (PSA) on the neural cell adhesion molecule 
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(NCAM) (54).  After developmental events cease, NCAM shifts from a PSA-rich to a 
PSA-poor form (21, 54, 56, 57).  Thus, one may expect the concentration of 
glycoprotein-bound sialic acid to decrease as maturation progresses.  
 Although the overall concentration of glycoprotein-bound sialic acid 
decreased in the second experiment, it remained significantly higher among rats fed 
the cholesterol-supplemented diet.  While it is possible that dietary cholesterol is 
slowing the maturational loss of PSA, it seems more probable that cholesterol is 
exerting an effect on glycoprotein-bound sialic acid by influencing the overall 
concentration of cortical protein.  Exposure to dietary cholesterol increased both 
cortical protein and glycoprotein-bound sialic acid.  However, the proportion of 
glycoprotein-bound sialic acid to total cortical protein remained stable across both 
dietary groups.  This suggests dietary cholesterol is not directly influencing the 
concentration of glycoprotein-bound sialic acid in the cortex.   
 
Analysis of Milk Cholesterol 
Whatley et al. demonstrated maternal hypercholesterolemia may increase the 
concentration of milk cholesterol in rabbits (104).  However, Green et al. did not 
observe a significant increase in the milk cholesterol of rats after administering a diet 
containing 15% lard and 1.5% cholesterol (w/w) from the 18th day of gestation until 
weaning (105).  The results of the present study contrast those obtained by Green et 
al., demonstrating that cholesterol intake by the dam increases total milk cholesterol.  
A potential limitation of our analysis is that we were not able to obtain milk directly 
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from the rats’ mammary glands, but removed coagulated milk from the stomachs of 
P1 rat pups.  However, P1 pups are not capable of consuming the maternal diets, and 
the contents of the pups’ stomachs only reflect milk intake and the presence of 
digestive fluids.  Differences in the cholesterol content of digestive fluids among pups 
receiving milk from cholesterol-supplemented dams seem unlikely.    
On the seventh day of lactation, Green et al. observed a milk cholesterol 
concentration of 71.7 ± 18.2 ( x ± SD) mg/dL in dams receiving a diet containing 
15% lard and 1.5% cholesterol (w/w) from the 18th day of gestation until weaning 
(105).  Although a similar value was obtained for milk collected from the stomachs of 
culled P1 pups consuming milk from cholesterol-supplemented dams, it is possible 
that digestive fluids diluted or absorption of water concentrated the milk in the rat 
pups’ stomachs.  Therefore, the concentration of cholesterol in the milk collected may 
not reflect the actual concentration produced by the dams.   
 
Limitations 
Other limitations of this study should be noted.  The source of CGMP in the 
modified AIN-93G diets varied between experiments one (Tatua Co-Operative Dairy 
Company, Morrinsville, New Zealand, 67 mg sialic acid/g) and two (Arla Food 
Ingredients, Denmark, 55 mg sialic acid/g), and each contained a slightly different 
proportion of protein-bound sialic acid.  Although the concentration of sialic acid was 
accounted for during the formulation of the four dietary treatments to produce diets 
with equivalent amounts of sialic acid, the overall composition of the diets varied 
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slightly.  Differences in the bioavailability of sialic acid were also possible.  This 
complicates comparisons made between the results of the two experiments.   
The pups in both experiments were fed CGMP as a source of sialic acid after 
the peak period of ganglioside-bound sialic acid accumulation.  They also consumed 
additional sialic acid and cholesterol that were inherent components of the dams’ milk 
for 17 or 21 days after birth.  Both of these factors would be expected to reduce the 
free capacity for sialic acid and cholesterol intake to influence brain composition.  
Finally, we could not determine whether the effects of maternal cholesterol 
supplementation during gestation influenced brain composition at birth because the 
P1 rat brains were not stored and available for analysis.  Such an analysis may be 
potentially misleading.  The P1 pups were available only from the largest litters, and 
larger litters were associated with smaller pup size at birth. 
 
Future Research 
The pups in experiments one and two were fed CGMP as a source of sialic 
acid after the peak period of ganglioside-bound sialic acid accumulation.  In humans, 
the total concentration of ganglioside-bound Neu5Ac in the forebrain increases in two 
distinct phases (59).  The first phase occurs between the 13th and 30th week of 
gestation, and the second occurs from birth to 9 months of age (59).  These phases 
correspond to the time of rapid multiplication of neurons and the extensive 
establishment of micro-neuronal interconnections, respectively (59).  The 
concentration of ganglioside-bound Neu5Ac in the cerebellum also increases from 
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birth to 9 months of age (59).  Further studies may be needed to determine the effect 
of maternal and neonatal sialic acid and cholesterol exposure on the accumulation of 
ganglioside- and glycoprotein-bound sialic acid in the brain during these critical 
periods.  It may also be important to determine if dietary sialic acid influences the 
expression of fucosyltransferases and the oligosaccharide composition of breast milk.   
 
Conclusions 
The results of the present study provide evidence that sialic acid contained in 
CGMP is bioavailable and can influence brain composition in developing rat pups.  
They also demonstrate that early consumption of sialic acid and cholesterol can 
accelerate the accumulation of ganglioside-bound sialic acid to a maximal 
concentration, but suggest animals will eventually reach this concentration even if 
they do not consume sialic acid or cholesterol.  The findings further suggest dietary 
cholesterol may be needed during the accumulation of ganglioside-bound sialic acid. 
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Chapter 6 Summary 
This study aimed to determine if CGMP and dietary cholesterol influence 
cortical ganglioside- and glycoprotein-bound sialic acid accumulation in young rats. 
Rat pups were allocated to one of four glycomacropeptide intakes, providing 
approximately 0, 20, 40 and 80 mg sialic acid/kg d-1 for two weeks, and exposed to 0 
or 0.5% dietary cholesterol by weight throughout gestation, lactation, and 
postweaning.  The concentration of ganglioside- and glycoprotein-bound sialic acid 
was determined through established methods (98, 99, 100), and the cholesterol 
content of the dams’ milk was determined according to Rosenthal et al. 
Milk cholesterol concentration was increased by maternal cholesterol intake 
from 55.8 to 70.5 mg/mL (p = 0.0009).  In pups sacrificed on P32, CGMP increased 
cortical ganglioside-bound sialic acid concentration in a dose-response manner (mg/g; 
p for trend = 0.007).  In the same experiment, dietary cholesterol independently 
increased ganglioside-bound sialic acid (p = 0.02).  In pups sacrificed between P38 
and P47, cholesterol intake increased glycoprotein-bound sialic acid (p = 0.030).   
The results of the present study provide evidence that the sialic acid contained 
in glycomacropeptide is bioavailable.  They demonstrate that early consumption of 
sialic acid and cholesterol can accelerate the accumulation of ganglioside-bound sialic 
acid to a maximal concentration, and they suggest dietary cholesterol may be 
important during the period of ganglioside-bound sialic acid accumulation. 
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Procedure for the Extraction of Gangliosides from Cortical Tissue 
 
1. Homogenize one hemisphere of cortex in an equal volume (w/v) of lysis 
buffer with a Sonics Vibra Cell for 1 minute at 20% maximum speed. 
 
2. Remove 250 μL of sample prepared as per number 1.  Add 875 μL of distilled 
water and vortex to mix.  Add 4 mL of 1:2 chloroform/methanol.  
 
3. Cap tube tightly with a Teflon-lined lid and vortex mixture for 30 minutes at 
room temperature. 
 
4. Centrifuge at 3300 rpm (1380 x G) for 30 minutes. 
 
5. Pour supernatant into clean 16 x 125 mm screw-top culture tube with a 
marking at 11 mL.  Cap tightly with a Teflon-lined lid. 
 
6. Reextract brain residue with an additional 5 mL of 4:8:3 
chloroform/methanol/water (v/v).  Cap tube tightly and vortex mixture for 30 
minutes at room temperature.  Centrifuge at 3300 rpm (1380 x G) for 30 
minutes. 
 
7. Combine supernatant with first extraction and add chloroform/methanol/water 
4:8:3 to 11 mL mark.  
 
8. Add 1.7 mL of water to the remaining 10 mL of extracted brain lipids to 
achieve a final chloroform/methanol/water ratio of 4:8:5.6.  
 
9. Mix by inversion 30 – 40 times.  Let mixture sit overnight at 4◦C or centrifuge 
15 minutes at 3300 rpm (1380 x G) to separate phases. 
 
10. Remove upper phase (contains gangliosides) and transfer to a new 16 x 125 
mm screw-top culture tube. 
 
11. Reextract the lower phase by adding 1.25 mL of methanol and 0.81 mL of 
0.01 M KCl.  Mix well by shaking. 
 
12. Centrifuge for 15 minutes at 3300 rpm (1380 x G).  Combine with first upper 
phase and dry under a stream of nitrogen in a 37◦C water bath.   
 
13. Dissolve residue of upper phase in 250 μL of chloroform/methanol/water 
60:30:4.5 (v/v).  Allow solution to sit at room temperature for 24 hours. 
 
14. Centrifuge to spin down any precipitate, and remove two 40 uL aliquots for 
sialic acid analysis. Store remaining sample at -20◦C. 
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Procedure for the Quantification of Ganglioside-Bound Neu5Ac 
 
1. Remove two 40 μL aliquots of each extracted ganglioside sample and place in 
two separate 16 x 125 mm screw-top culture tubes with Teflon-lined lids. 
 
2. Dry under a stream of nitrogen in a 37◦C water bath. 
 
3. While samples are drying, prepare standards (0, 2, 5, 10, 20, 30, and 40 μg/0.5 
mL) using the volume of 0.20 μg/μL stock sialic acid solution and water 
specified for each standard in the following table: 
 
Standard (μg/500 μL) Volume of 0.20 μg/μL Stock Sialic Acid Solution Volume of Water 
0 0 μL 500 μL 
2 10 μL 490 μL 
5 25 μL 475 μL 
10 50 μL 450 μL 
20 100 μL 400 μL 
30 150 μL 350 μL 
40 200 μL 300 μL 
 
 
4. After samples are dry, dissolve residue in 0.5 mL of distilled water.  Vortex 
for 5 minutes to mix. 
 
5. Add 0.5 mL of the resorcinol-HCl reagent to each sample and standard. 
 
Preparation of resorcinol-HCl reagent: 
  
Combine 4.875 mL of distilled water with 125 μL of 0.1 M copper (II) 
sulfate pentahydrate and 5 mL of 2% resorcinol (2 g of resorcinol 
dissolved in 100 mL of distilled water).  (Stable several months at 4◦C) 
 
Add 40 mL of concentrated HCl (37%, 12 N) and mix well. 
 
Resorcinol-HCl reagent must be prepared at least 4 hours before use. 
(Stable 1 week at 4◦C.)  
 
6. Vortex samples for 5 minutes. 
 
7.  Heat culture tubes for 25 minutes in a boiling water bath to develop color. 
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8. After heating, cool tubes in running water; add 1.5 mL of butylacetate/butanol 
(85/15, v/v).  Vortex for 5 minutes, then place in ice water for 15 minutes. 
 
9. Centrifuge for 1 minute at 3300 rpm (1380 x G). 
 
10. Place culture tubes in ice water again until photometric readings are taken.   
 
11. To obtain absorbance value, pipet the upper, colored phase into a cuvette 
using a transfer pipet and read at 620 nm with a BioSpec-mini 
spectrophotometer.   
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Procedure for the Quantification of Glycoprotein-Bound Neu5Ac 
 
1. Dry each glycoprotein sample under a stream of nitrogen in a 37◦C water bath 
to remove any residual extraction solvent. 
 
2. While samples are drying, prepare standards (0, 2, 5, 10, 20, 30, and 40 μg/0.5 
mL) using the volume of 0.20 μg/μL stock sialic acid solution and water 
specified for each standard in the following table: 
 
 
Standard (μg/500 μL) Volume of 0.20 μg/μL Stock Sialic Acid Solution Volume of Water 
0 0 μL 500 μL 
2 10 μL 490 μL 
5 25 μL 475 μL 
10 50 μL 450 μL 
20 100 μL 400 μL 
30 150 μL 350 μL 
40 200 μL 300 μL 
 
 
3. After samples are dry, dissolve residue in 1.0 mL of distilled water.  Vortex 
for 5 minutes to mix. 
 
4. Add 0.5 mL and 1.0 mL of the resorcinol-HCl reagent to each standard and 
sample, respectively. 
 
Preparation of resorcinol-HCl reagent: 
  
Combine 4.875 mL of distilled water with 125 μL of 0.1 M copper (II) 
sulfate pentahydrate and 5 mL of 2% resorcinol (2 g of resorcinol 
dissolved in 100 mL of distilled water).  (Stable several months at 4◦C) 
 
Add 40 mL of concentrated HCl (37%, 12N) and mix well. 
 
Resorcinol-HCl reagent must be prepared at least 4 hours before use. 
(Stable for 1 week at 4◦C.)  
 
5. Vortex samples for 5 minutes. 
 
6. Heat culture tubes for 25 minutes in a boiling water bath to develop color. 
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7. After heating, cool tubes in running water; add 1.5 mL and 3.0 mL of 
butylacetate/butanol (85/15, v/v) to each standard and sample, respectively.  
Vortex for 5 minutes, then place in ice water for 15 minutes. 
 
8. Centrifuge for 1 minute at 3300 rpm (1380 x G). 
 
9. Place culture tubes in ice water again until photometric readings are taken.   
 
10. To obtain absorbance value, pipet the upper, colored phase into a cuvette 
using a transfer pipet and read at 620 nm with a BioSpec-mini 
spectrophotometer. 
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Procedure for the Analysis of Total Cholesterol in Milk 
 
1. Thaw frozen milk samples and sonicate for 1 minute at 20% maximum 
amplitude (Sonics Vibra Cell).  
 
2. Pipet 25 µL of the homogenized milk samples into separate 16 x 125 mm 
screw-top culture tubes. 
 
3. Add 250 µL of ethanolic potassium hydroxide solution to each tube.   
 
Preparation of potassium hydroxide solution: 
 
Dissolve 5 g of reagent grade KOH in 10 mL of water to form 33% 
KOH (w/v) solution. 
 
Preparation of ethanolic potassium hydroxide solution: 
 
Add 6.06 mL of 33% KOH (w/v in H20) to 13.94 mL of absolute 
ethanol to form a 10% KOH solution (w/v). 
 
Solution must be prepared immediately before use!  
 
4.  Cap each tube tightly with a Teflon-lined lid and vortex 3 minutes to mix. 
 
5. Incubate tubes in a water bath set at 37 – 40ºC for 55 minutes. 
 
6. After cooling to room temperature, add 0.5 mL of petroleum ether and vortex 
5 minutes to mix. 
 
7. Add 250 µL of water to each tube and vortex vigorously for 1 minute. 
 
8. Centrifuge tubes at 3300 rpm (1380 x G) for 3 minutes or until the emulsion 
breaks and two clear layers form. 
 
9. Freeze the lower phase in an acetone-dry ice bath for 3 minutes and pipet 
upper phase (petroleum ether layer) into new, separate 16 x 125 mm screw-
top culture tube.  (The extraction can be interrupted at this stage, and the tubes 
capped and stored at 4ºC until analysis.) 
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10. Place the tubes in a water bath set at 60ºC and evaporate the petroleum ether 
layer under a stream of nitrogen.  
 
11. While samples are drying, prepare standards (0, 5, 10, 15, 20, 25, and 30 
µg/2.5 mL) using the volume of 0.5 µg/µL stock cholesterol solution and 
glacial acetic acid specified for each standard in the following table: 
Standard (μg/2.5 mL) Volume of 0.5 μg/μL Stock Cholesterol Solution 
Volume of Glacial 
Acetic Acid 
0                     0 μL 2.50 mL 
5 10 μL 2.49 mL 
10 20 μL 2.48 mL 
15 30 μL 2.47 mL 
20 40 μL 2.46 mL 
25 50 μL 2.45 mL 
30 60 μL 2.44 mL 
                                                                                                                                                                       
12. Reconstitute the residue with 2.5 mL of glacial acetic acid and mix well to 
dissolve.  (If needed, warm the acetic acid to 70ºC to aid dissolution.) 
 
13. Add 2 mL of the color reagent to the samples and standards; mix gently, but 
thoroughly.  (Avoid vigorous shaking, which produces bubbles.) 
 
Note:  If the acetic acid was warmed in the previous step, allow the 
samples to cool to room temperature before adding the color reagent. 
 
Preparation of the iron stock solution: 
 
Dissolve 2.5 g of FeCl3·6H20 in 100 mL of phosphoric acid (85%). 
(Stable indefinitely at room temperature.) 
 
Preparation of the color reagent: 
 
 Dilute 16.0 mL of iron stock solution to 200 mL with concentrated 
sulfuric acid (98%). (Stable 8 weeks at room temperature if protected 
from atmospheric moisture.) 
 
14. Determine the absorbance 30 minutes after mixing and read at 560 nm. 
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Mean Concentrations of Cortical Ganglioside-bound Sialic Acid in Rats Fed 
Diets Containing 0% and 0.5% Cholesterol by Weight 
mg sialic acid/kg/d Non-Cholesterol Diet Cholesterol Diet 
0 919.76 μg/g             983.80 μg/g 
20 953.08 μg/g 1017.13 μg/g 
40 986.41 μg/g  1050.46 μg/g 
80            1019.73 μg/g 1083.78 μg/g 
 
Differences in ganglioside-bound sialic acid were determined using a mixed 
model ANOVA (SAS® version 9.2, SAS Institute Inc., Cary, NC).  
Glycomacropeptide independently and significantly increased (linear trend for 
dose) cortical ganglioside-bound sialic acid (p = 0.007) (n = 10 at 0 mg sialic 
acid/kd·d-1; n = 11 at all other levels of supplementation).  Dietary cholesterol 
significantly increased ganglioside-bound sialic acid (p = 0.02) (n = 10 at 40 mg 
sialic acid/kd·d-1; n = 11 at all other levels of supplementation). 
 
 
